Scientists have developed a groundbreaking AI-driven vaccine technology designed to provide extensive immunity against entire families of viruses and their future mutations with a single injection. This innovative 'super-antigen' approach, created by researchers at the University of Cambridge and DIOSynVax, aims to prevent future pandemics, potentially saving millions of lives and negating the need for lockdowns. A world-first Phase I human trial of a universal Sarbeco coronavirus vaccine demonstrated its safety and triggered an immune response against SARS-CoV-2, SARS, and related bat viruses. The vaccine utilizes a needle-free microfluid jet for administration, delivering vaccine blueprints directly into skin cells. Experts, including Professor Jonathan Heeney and Professor Saul Faust, regard this development as a significant paradigm shift in vaccine development, providing 'future-proofed' protection against emerging pathogens.